These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer. Lottner C; Schwarz S; Diermeier S; Hartmann A; Knuechel R; Hofstaedter F; Brockhoff G J Pathol; 2005 Apr; 205(5):577-84. PubMed ID: 15732132 [TBL] [Abstract][Full Text] [Related]
24. Clinicopathological features and treatment outcomes of the rare, salivary duct carcinoma of parotid gland. Al-Qahtani KH; Tunio MA; Bayoumi Y; Gurusamy VM; Bahamdain FA; Fatani H J Otolaryngol Head Neck Surg; 2016 May; 45(1):32. PubMed ID: 27184361 [TBL] [Abstract][Full Text] [Related]
25. Trastuzumab for the treatment of salivary duct carcinoma. Limaye SA; Posner MR; Krane JF; Fonfria M; Lorch JH; Dillon DA; Shreenivas AV; Tishler RB; Haddad RI Oncologist; 2013; 18(3):294-300. PubMed ID: 23429737 [TBL] [Abstract][Full Text] [Related]
26. MicroRNA Profiling of Salivary Duct Carcinoma Versus Her2/Neu Overexpressing Breast Carcinoma Identify miR-10a as a Putative Breast Related Oncogene. Balatti V; Oghumu S; Bottoni A; Maharry K; Cascione L; Fadda P; Parwani A; Croce C; Iwenofu OH Head Neck Pathol; 2019 Sep; 13(3):344-354. PubMed ID: 30259272 [TBL] [Abstract][Full Text] [Related]
27. EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis. Ettl T; Stiegler C; Zeitler K; Agaimy A; Zenk J; Reichert TE; Gosau M; Kühnel T; Brockhoff G; Schwarz S Hum Pathol; 2012 Jun; 43(6):921-31. PubMed ID: 22154363 [TBL] [Abstract][Full Text] [Related]
28. Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes. Di Palma S; Simpson RH; Marchiò C; Skálová A; Ungari M; Sandison A; Whitaker S; Parry S; Reis-Filho JS Histopathology; 2012 Oct; 61(4):629-43. PubMed ID: 22882517 [TBL] [Abstract][Full Text] [Related]
29. The role of trastuzumab in the management of salivary ductal carcinomas. Perissinotti AJ; Lee Pierce M; Pace MB; El-Naggar A; Kies MS; Kupferman M Anticancer Res; 2013 Jun; 33(6):2587-91. PubMed ID: 23749912 [TBL] [Abstract][Full Text] [Related]
30. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland. Cornolti G; Ungari M; Morassi ML; Facchetti F; Rossi E; Lombardi D; Nicolai P Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1031-6. PubMed ID: 17938328 [TBL] [Abstract][Full Text] [Related]
31. Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy. Diaz NM Cancer Control; 2001; 8(5):415-8. PubMed ID: 11579337 [TBL] [Abstract][Full Text] [Related]
32. NCOA4-RET and TRIM27-RET Are Characteristic Gene Fusions in Salivary Intraductal Carcinoma, Including Invasive and Metastatic Tumors: Is "Intraductal" Correct? Skálová A; Ptáková N; Santana T; Agaimy A; Ihrler S; Uro-Coste E; Thompson LDR; Bishop JA; Baněčkova M; Rupp NJ; Morbini P; de Sanctis S; Schiavo-Lena M; Vanecek T; Michal M; Leivo I Am J Surg Pathol; 2019 Oct; 43(10):1303-1313. PubMed ID: 31162284 [TBL] [Abstract][Full Text] [Related]
33. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression. Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of HER2/neu expression in different types of salivary gland tumors: a systematic review and meta-analysis. Javaheripour A; Saatloo MV; Vahed N; Gavgani LF; Kouhsoltani M J Med Life; 2022 May; 15(5):595-600. PubMed ID: 35815077 [TBL] [Abstract][Full Text] [Related]
35. Salivary duct carcinoma of the parotid gland: is adjuvant HER-2-targeted therapy required? Lee JS; Kwon OJ; Park JJ; Seo JH J Oral Maxillofac Surg; 2014 May; 72(5):1023-31. PubMed ID: 24480767 [TBL] [Abstract][Full Text] [Related]
36. HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved Hercep test. Scheurle D; Jahanzeb M; Aronsohn RS; Watzek L; Narayanan R Anticancer Res; 2000; 20(3B):2091-6. PubMed ID: 10928158 [TBL] [Abstract][Full Text] [Related]
37. Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. Prat A; Parera M; Reyes V; Peralta S; Cedrés S; Andreu J; Huguet P; del Campo JM Head Neck; 2008 May; 30(5):680-3. PubMed ID: 17972317 [TBL] [Abstract][Full Text] [Related]
38. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies. Singer CF; Köstler WJ; Hudelist G Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208 [TBL] [Abstract][Full Text] [Related]
39. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Jaehne M; Roeser K; Jaekel T; Schepers JD; Albert N; Löning T Cancer; 2005 Jun; 103(12):2526-33. PubMed ID: 15900577 [TBL] [Abstract][Full Text] [Related]
40. Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment. Falchook GS; Lippman SM; Bastida CC; Kurzrock R Head Neck; 2014 Mar; 36(3):E25-7. PubMed ID: 23852769 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]